Oncologist:中国,印度和巴基斯坦青年肿瘤学家分析癌症治疗的区域差异

2015-04-20 范伟译 MedSci原创

背景: 癌症发病率和死亡率在发展中国家正在增加。低收入、中等和高收入国家之间的不平等影响着应对癌症的疾病负担和基础设施的需求。我们调查新兴经济体三个国家的参加临床研究研讨会的青年肿瘤学家对涉及癌症负担的认知情况。 方法: 横断面问卷调查发布在北京,拉合尔,卡拉奇和孟买大医院举办的临床试验概念发展研讨会上,再收集原籍国相关的健康状况和需求方面的信息。 结果: 共有100名受访者参与在该地区大医院

背景: 癌症发病率和死亡率在发展中国家正在增加。低收入、中等和高收入国家之间的不平等影响着应对癌症的疾病负担和基础设施的需求。我们调查新兴经济体三个国家的参加临床研究研讨会的青年肿瘤学家对涉及癌症负担的认知情况。

方法: 横断面问卷调查发布在北京,拉合尔,卡拉奇和孟买大医院举办的临床试验概念发展研讨会上,再收集原籍国相关的健康状况和需求方面的信息。

结果: 共有100名受访者参与在该地区大医院举行的研讨会 (印度=29,中国=25,巴基斯坦=42,其他=4)。许多问题预期达成共识(癌症的出现作为一个重大的健康问题),在优先次序,机会和挑战上与重要的变量相平等。中国受访者把改善癌症特异的治疗和姑息治疗放在首位,印度受访者赞成改善癌症检测和推进癌症治疗的研究,巴基斯坦受访者把癌症意识放在优先位置,改善疾病检测和癌症治疗的研究。最常提到的机会是帮助改善癌症专业化的教育和培训。

结论: 青年肿瘤学家作为主导参加的临床研究研讨会(在中国、印度和巴基斯坦)确定要增加临床癌症研究、专业化教育、癌症公众意识的需求。在他们国家优先考虑卫生政策和预算的前提下,决策者支持努力减少全球癌症负担将需要卫生保健提供者特定的需求和愿望。

原始出处

Lyerly HK1, Fawzy MR2, Aziz Z2, Nair R2, Pramesh CS2, Parmar V2, Parikh PM2, Jamal R2, Irumnaz A2,Ren J2, Stockler MR2, Abernethy AP2. Regional Variation in Identified Cancer Care Needs of Early-Career Oncologists in China, India, and Pakistan. Oncologist. 2015 Apr 17.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864641, encodeId=cc5f18646418c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 21 02:46:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844162, encodeId=0ba61844162b4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Tue Nov 03 13:46:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724775, encodeId=a30e1e24775b0, content=<a href='/topic/show?id=d8e348286e1' target=_blank style='color:#2F92EE;'>#巴基斯坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48286, encryptionId=d8e348286e1, topicName=巴基斯坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cfb33680772, createdName=apoenzyme, createdTime=Fri May 08 21:46:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390740, encodeId=2a3d1390e40eb, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Apr 22 00:46:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455115, encodeId=f0561455115a3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Apr 22 00:46:00 CST 2015, time=2015-04-22, status=1, ipAttribution=)]
    2015-05-21 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1864641, encodeId=cc5f18646418c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 21 02:46:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844162, encodeId=0ba61844162b4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Tue Nov 03 13:46:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724775, encodeId=a30e1e24775b0, content=<a href='/topic/show?id=d8e348286e1' target=_blank style='color:#2F92EE;'>#巴基斯坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48286, encryptionId=d8e348286e1, topicName=巴基斯坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cfb33680772, createdName=apoenzyme, createdTime=Fri May 08 21:46:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390740, encodeId=2a3d1390e40eb, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Apr 22 00:46:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455115, encodeId=f0561455115a3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Apr 22 00:46:00 CST 2015, time=2015-04-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1864641, encodeId=cc5f18646418c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 21 02:46:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844162, encodeId=0ba61844162b4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Tue Nov 03 13:46:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724775, encodeId=a30e1e24775b0, content=<a href='/topic/show?id=d8e348286e1' target=_blank style='color:#2F92EE;'>#巴基斯坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48286, encryptionId=d8e348286e1, topicName=巴基斯坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cfb33680772, createdName=apoenzyme, createdTime=Fri May 08 21:46:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390740, encodeId=2a3d1390e40eb, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Apr 22 00:46:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455115, encodeId=f0561455115a3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Apr 22 00:46:00 CST 2015, time=2015-04-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1864641, encodeId=cc5f18646418c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 21 02:46:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844162, encodeId=0ba61844162b4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Tue Nov 03 13:46:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724775, encodeId=a30e1e24775b0, content=<a href='/topic/show?id=d8e348286e1' target=_blank style='color:#2F92EE;'>#巴基斯坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48286, encryptionId=d8e348286e1, topicName=巴基斯坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cfb33680772, createdName=apoenzyme, createdTime=Fri May 08 21:46:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390740, encodeId=2a3d1390e40eb, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Apr 22 00:46:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455115, encodeId=f0561455115a3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Apr 22 00:46:00 CST 2015, time=2015-04-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1864641, encodeId=cc5f18646418c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 21 02:46:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844162, encodeId=0ba61844162b4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Tue Nov 03 13:46:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724775, encodeId=a30e1e24775b0, content=<a href='/topic/show?id=d8e348286e1' target=_blank style='color:#2F92EE;'>#巴基斯坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48286, encryptionId=d8e348286e1, topicName=巴基斯坦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cfb33680772, createdName=apoenzyme, createdTime=Fri May 08 21:46:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390740, encodeId=2a3d1390e40eb, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Apr 22 00:46:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455115, encodeId=f0561455115a3, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Wed Apr 22 00:46:00 CST 2015, time=2015-04-22, status=1, ipAttribution=)]
    2015-04-22 july_977

相关资讯

Nano Letters:新型抗癌纳米技术可直接将药物运输至肿瘤“心脏”发挥作用

近日,发表在国际杂志Nano Letters上的一篇研究论文中,来自韩国科学技术研究所的研究人员通过研究开发了一种新型高效的抗癌纳米技术,其可以将抗癌药物均匀地运输至整个肿瘤组织。科学家们常常利用抗癌药物来治疗不能进行手术的肿瘤,然而将药物运输至肿瘤细胞通常比较困难,尤其是将药物覆盖整个肿瘤组织更是难如登天;利用前的药物运输系统,比如纳米技术,一种药物就可以被仅仅运输到血管附近的肿瘤细胞处,但对肿

为何丹麦癌症发病率世界**?

根据世界卫生组织资料,2012年丹麦癌症发病率世界排名第一,同时丹麦人均生活垃圾焚烧量也是世界第一。垃圾焚烧会产生二恶英,二恶英被世界卫生组织国际癌症研究所列为“已知人类致癌物”。这似乎验证了一个多年的推测,垃圾焚烧率高的国家通常会有高的癌症发病率,我们想通过相关数据对比,寻找更多的证据,证实这种关联性。 癌症发病有多种原因,以肺癌为例,有些国家大气污染严重也会导致肺癌增加,但发达国家常规空

PNAS:科学家发现新可代替mTOR的调控蛋白生产的途径

电镜下的MCV(Merkel细胞多瘤病毒)技术和科学发现的偶然组合,再加上一种预感,使得美国匹兹堡大学癌症研究所(UPCI)的研究人员揭示先前未被发现的一个的生物途径,可能部分解释了为何癌症细胞如此快速增长。一个众所周知的癌症蛋白—mTOR,以前被认为是全权负责控制肿瘤细胞蛋白质生产的重要形式—帽依赖性翻译。Shuda博士和他的同事们发现,实际上mTOR的功能在细胞分裂情况下可以被另一个不同的蛋白

Nature:重要论文修正癌症研究前论

Weill Cornell医学院的研究人员在尝试去验证以往报道的关于三阴性乳腺癌的一个分子发现(许多人曾满怀希望该研究发现可以促使开发出针对这种侵袭性癌症的靶向疗法)时,转而证实了这一研究结果只限于一名患者,而无法应用于进一步的临床研究工作。这一发表在4月15日Nature杂志上的研究发现修正了早期的研究工作,并强调了独立研究验证和小心研发实验方法的重要性。 这一由麻省理工学院和哈佛大学

JECH:孕期补充叶酸对孕妇是安全的

备孕期和怀孕前三月常规要求女性/孕妇补充叶酸以减少胎儿神经管缺陷风险。先前观察结果暗示每天摄入5 mg叶酸的孕妇较之安慰剂对照组,其将来的生活中患乳腺癌风险增加,不仅如此,因其他癌症导致死亡的风险也会增加。

Cell:iPSC——家族性癌症研究新模型

最近利用诱导多能干细胞技术对人类疾病进行体外建模已经成为一种可行方法。来自美国的科学家利用李弗劳明综合征病人的体细胞建立了诱导多能干细胞,并利用该细胞系向osteoblast方向分化,进行了相关基因表达分析,发现分化后的细胞系能够很好的模拟骨肉瘤的肿瘤特征。最近,相关研究成果发表在著名国际学术期刊 Cell。 研究人员从患有一种p53基因突变性家族疾病(李弗劳明综合征)的病人身上获得细胞进行